Information Provided By:
Fly News Breaks for February 14, 2018
LXRX
Feb 14, 2018 | 06:58 EDT
JPMorgan analyst Jessica Fye downgraded Lexicon Pharmaceuticals to Underweight and lowered her price target for the shares to $10 from $15. The Xermelo launch remains slow, and consensus estimates of $55M and $99M for 2018 and 2019 are too high, Fye tells investors in a research note. The analyst sees more risks for the stock to underperform with limited catalysts in the year to drive meaningful upside beyond an "outright competitor stumble" in type 1 diabetes.
News For LXRX From the Last 2 Days
There are no results for your query LXRX